Pediatric Psoriasis: Infection Risk Low With Systemic Meds Pediatric Psoriasis: Infection Risk Low With Systemic Meds
The results are from a large cohort study that estimated the 6-month rate of infections among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate.MDedge News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news
More News: Children | Dermatology | Enbrel | Methotrexate | Pediatrics | Psoriasis | Skin | Stelara | Study